CPRX vs. XPEL
Compare and contrast key facts about Catalyst Pharmaceuticals, Inc. (CPRX) and XPEL, Inc. (XPEL).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: CPRX or XPEL.
Correlation
The correlation between CPRX and XPEL is 0.18, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Performance
CPRX vs. XPEL - Performance Comparison
Loading data...
Key characteristics
CPRX:
1.19
XPEL:
0.17
CPRX:
1.95
XPEL:
0.84
CPRX:
1.22
XPEL:
1.10
CPRX:
1.65
XPEL:
0.12
CPRX:
6.46
XPEL:
0.46
CPRX:
7.40%
XPEL:
18.94%
CPRX:
41.35%
XPEL:
68.92%
CPRX:
-94.25%
XPEL:
-99.77%
CPRX:
-5.32%
XPEL:
-62.75%
Fundamentals
CPRX:
$2.97B
XPEL:
$1.04B
CPRX:
$1.57
XPEL:
$1.72
CPRX:
15.52
XPEL:
21.96
CPRX:
5.56
XPEL:
2.41
CPRX:
3.65
XPEL:
4.40
CPRX:
$534.65M
XPEL:
$434.10M
CPRX:
$441.72M
XPEL:
$183.38M
CPRX:
$250.28M
XPEL:
$68.88M
Returns By Period
In the year-to-date period, CPRX achieves a 16.77% return, which is significantly higher than XPEL's -5.43% return. Over the past 10 years, CPRX has underperformed XPEL with an annualized return of 19.87%, while XPEL has yielded a comparatively higher 31.00% annualized return.
CPRX
16.77%
8.21%
18.30%
47.79%
40.03%
19.87%
XPEL
-5.43%
46.17%
-15.65%
12.24%
22.39%
31.00%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
CPRX vs. XPEL — Risk-Adjusted Performance Rank
CPRX
XPEL
CPRX vs. XPEL - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Catalyst Pharmaceuticals, Inc. (CPRX) and XPEL, Inc. (XPEL). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Loading data...
Dividends
CPRX vs. XPEL - Dividend Comparison
Neither CPRX nor XPEL has paid dividends to shareholders.
Drawdowns
CPRX vs. XPEL - Drawdown Comparison
The maximum CPRX drawdown since its inception was -94.25%, smaller than the maximum XPEL drawdown of -99.77%. Use the drawdown chart below to compare losses from any high point for CPRX and XPEL. For additional features, visit the drawdowns tool.
Loading data...
Volatility
CPRX vs. XPEL - Volatility Comparison
The current volatility for Catalyst Pharmaceuticals, Inc. (CPRX) is 10.00%, while XPEL, Inc. (XPEL) has a volatility of 17.43%. This indicates that CPRX experiences smaller price fluctuations and is considered to be less risky than XPEL based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading data...
Financials
CPRX vs. XPEL - Financials Comparison
This section allows you to compare key financial metrics between Catalyst Pharmaceuticals, Inc. and XPEL, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
CPRX vs. XPEL - Profitability Comparison
CPRX - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Catalyst Pharmaceuticals, Inc. reported a gross profit of 123.51M and revenue of 141.42M. Therefore, the gross margin over that period was 87.3%.
XPEL - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, XPEL, Inc. reported a gross profit of 43.90M and revenue of 103.81M. Therefore, the gross margin over that period was 42.3%.
CPRX - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Catalyst Pharmaceuticals, Inc. reported an operating income of 63.37M and revenue of 141.42M, resulting in an operating margin of 44.8%.
XPEL - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, XPEL, Inc. reported an operating income of 11.12M and revenue of 103.81M, resulting in an operating margin of 10.7%.
CPRX - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Catalyst Pharmaceuticals, Inc. reported a net income of 56.74M and revenue of 141.42M, resulting in a net margin of 40.1%.
XPEL - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, XPEL, Inc. reported a net income of 8.59M and revenue of 103.81M, resulting in a net margin of 8.3%.